Exelixis
EXEL
#1695
Rank
C$14.18 B
Marketcap
$49.67
Share price
-3.83%
Change (1 day)
59.04%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.38

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.41. In 2022 the company made an earnings per share (EPS) of $0.82 a decrease over its 2021 EPS that were of $1.06.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.38-53.95%
2022$0.82-22.97%
2021$1.06100%
2020$0.53-65.09%
2019$1.52-53.91%
2018$3.29333.96%
2017$0.76-260.61%
2016-$0.47-58.75%
2015-$1.15-42.45%
2014-$1.995.3%
2013-$1.8943.48%
2012-$1.32-264.29%
2011$0.80-165.88%
2010-$1.22-32.54%
2009-$1.80-17.65%
2008-$2.1975.86%
2007-$1.25-25.64%
2006-$1.688.33%
2005-$1.55-42.86%
2004-$2.7130.34%
2003-$2.08-5.23%
2002-$2.19-0.65%
2001-$2.21-51.88%
2000-$4.58

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$5.01 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.55 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.61 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.68 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$20.26 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$20.17 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.66 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$14.32-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.20-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA